首页> 外文OA文献 >Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial

【2h】

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial

机译：利妥昔单抗联合吉西他滨和奥沙利铂用于难治性/复发性弥漫性大B细胞淋巴瘤患者，不适合大剂量治疗。 II期淋巴瘤研究协会试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mounier, N.; El Gnaoui, T.; Tilly, H.; Canioni, D.; Sebban, C.; Casasnovas, R.-O.; Delarue, R.; Sonet, Anne; Beaussart, P.; Petrella, T.; Castaigne, S.; Bologna, S.; Salles, G.; Rahmouni, A.; Gaulard, P.; Haioun, C.;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. [J] . El-Gnaoui T, Dupuis J, Belhadj K, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第8期

机译：利妥昔单抗，吉西他滨和奥沙利铂：对于复发或难治性B细胞淋巴瘤而不适合大剂量治疗的患者，有效的治疗方案。
2. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy [J] . T El Gnaoui1†† J Dupuis1†† K Belhadj1 J-P Jais2 A Rahmouni3 C Copie-Bergman4 I Gaillard1 M Diviné1 I Tabah-Fisch5 F Reyes1† and C Haioun1 Annals of Oncology . 2007,第8期

机译：利妥昔单抗，吉西他滨和奥沙利铂：对于复发性或难治性B细胞淋巴瘤而不适合大剂量治疗的患者，有效的治疗方案
3. Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B [J] . Molina Thierry Jo, Canioni Danielle, Copie-Bergman Christiane, Journal of Clinical Oncology . 2014,第35期

机译：非生发中心B细胞的年轻患者脱差大B细胞淋巴瘤与ACVBP Plus rituximab的加强化疗与Chop Plus Rituximab相比：来自Groupe D'Etudes des Lymphomes de L'淋巴瘤研究的数据分析协会第III期试验LNH 03-2B
4. Mutational profile of Diffuse Large B-cell Lymphoma with central nervous system relapse: analysis of CBioPortal for Cancer Genomics database [C] . Elena Voropaeva, Olga Beresina, Tatyana Pospelova, Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征：用于癌症基因组学数据库的CBioPortal分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial [O] . Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, 2013

机译：利妥昔单抗联合吉西他滨和奥沙利铂用于难治性/复发性弥漫性大B细胞淋巴瘤患者不适合大剂量治疗。 II期淋巴瘤研究协会试验
7. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma [O] . Monica Balzarotti, Massimo Magagnoli, Miguel Ángel Canales, 2021

机译：抗CD37单克隆抗体，BI 836826的相位IB，开放标签，剂量升级试验，与吉西他滨和Oxaliplatin组合在复发/难治性弥漫性大B细胞淋巴瘤患者中

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial

著录项

引文网络

相似文献

相关主题

期刊订阅